Ocugen, Inc. (OCGN): Total Assets
$43.52M
As of 2025-12-31
$124.21M
As of 2026-06-30
-26.3%
3-year compound annual growth
+9.7%
5-year compound annual growth
+1.7%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $43.52M | -47.2% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $82.44M | +27.7% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $64.55M | n/a | 2025-03-05, Balance as of period end |
| 2023-09-30 | $74.69M | n/a | 2024-04-16, Balance as of period end |
| 2023-06-30 | $88.98M | n/a | 2024-04-16, Balance as of period end |
| 2023-03-31 | $96.30M | n/a | 2024-04-16, Balance as of period end |
| 2022-12-31 | $108.63M | n/a | 2024-04-16, Balance as of period end |
| 2022-09-30 | $116.24M | n/a | 2024-04-16, Balance as of period end |
| 2022-06-30 | $130.09M | n/a | 2024-04-16, Balance as of period end |
| 2022-03-31 | $141.73M | n/a | 2024-04-16, Balance as of period end |
| 2021-12-31 | $105.76M | +286.3% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $27.38M | +62.9% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $16.81M | +584.8% | 2021-03-19, Balance as of period end |
| 2018-12-31 | $2.45M | -77.8% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $11.04M | -69.4% | 2019-03-22, Balance as of period end |
| 2016-12-31 | $36.08M | -1.9% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $36.79M | -43.8% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $65.50M | n/a | 2016-03-10, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
Compare OCGN, PRME, CGON, ZEOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗